Compare U.S. Stocks

Put up to three companies side by side on valuation, growth, profitability, and debt.

Metric	ABBVAbbVie	AMGNAmgen	GILDGilead Sciences
Snapshot
Price	$245.59	$407.36	$133.81
Market cap	$461.26B	$201.93B	$162.98B
Valuation
P/E	118.4x	28.4x	17.9x
Forward P/E	136.8x	21.6x	12.8x
Growth
Revenue growth	9.5%	9.1%	3.5%
EPS growth	-13.5%	31.3%	55.5%
Profitability
Net margin	5.8%	21.0%	31.0%
ROE	95.6%	89.4%	42.2%
Balance sheet & cash
Debt / equity	20.19x	6.31x	1.1x
Free cash flow yield	3.9%	6.0%	5.2%
Dividend yield	3.1%	2.9%	2.6%
Verdict
Investment rating	Weak· 31	Favorable· 62	Strong· 74

5-Year Price Projections

Base case

Projected using each stock's current EPS, growth rate (EPS or revenue growth), and P/E ratio. P/E assumed to compress 25% on the low end and remain steady on the high end. Not a forecast — for comparative analysis only.

Year	ABBVtoday $246	AMGNtoday $407	GILDtoday $134
2027	$187.88 – $275.55+12% CAGR	$401.06 – $588.22+44% CAGR	$156.05 – $228.87+71% CAGR
2028	$191.63 – $281.06+7% CAGR	$526.47 – $772.15+38% CAGR	$242.64 – $355.87+63% CAGR
2029	$195.47 – $286.68+5% CAGR	$691.09 – $1,013.60+36% CAGR	$377.27 – $553.34+61% CAGR
2030	$199.38 – $292.42+4% CAGR	$907.20 – $1,330.56+34% CAGR	$586.62 – $860.38+59% CAGR
2031	$203.36 – $298.27+4% CAGR	$1,190.88 – $1,746.62+34% CAGR	$912.14 – $1,337.81+58% CAGR
5-yr CAGR	-3.7% – 4.0%	23.9% – 33.8%	46.8% – 58.5%